Premium
Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities
Author(s) -
Mohseni Afshar Zeinab,
Babazadeh Arefeh,
Janbakhsh Alireza,
Mansouri Feizollah,
Sio Terence T.,
Sullman Mark J. M.,
CarsonChahhoud Kristin,
Hosseinzadeh Rezvan,
Barary Mohammad,
Ebrahimpour Soheil
Publication year - 2022
Publication title -
reviews in medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.06
H-Index - 90
eISSN - 1099-1654
pISSN - 1052-9276
DOI - 10.1002/rmv.2309
Subject(s) - medicine , pandemic , vaccination , disease , population , intensive care medicine , immunology , coronavirus , comorbidity , obesity , pediatrics , covid-19 , infectious disease (medical specialty) , environmental health
Summary Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid‐19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid‐19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end‐stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence.